

## RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE

### Validation of an original ETP-based APC resistance assay for the evaluation of prothrombotic states

Morimont, Laure; Bouvy, Céline; Dogné, Jean-Michel; Douxfils, Jonathan

*Publication date:*  
2019

*Document Version*  
Publisher's PDF, also known as Version of record

#### [Link to publication](#)

*Citation for published version (HARVARD):*

Morimont, L, Bouvy, C, Dogné, J-M & Douxfils, J 2019, 'Validation of an original ETP-based APC resistance assay for the evaluation of prothrombotic states', ISTH 2019 : The XXVII Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australia, 6/07/19 - 10/07/19.

#### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

#### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

## BACKGROUND

- ❖ The activated protein C resistance assay based on the endogenous thrombin potential (ETP-based APCr assay) is recommended in guidance from medicines regulatory authorities (e.g. EMA and FDA) for the investigation of steroid contraceptives.<sup>1</sup>
- ❖ The results are usually “normalized” with a reference plasma to provide the “normalized APC sensitivity ratio” (nAPCsr).<sup>2</sup>
- ❖ However, the methods described in the literature are home-made and mostly without standardization of the method, the reagents, the reference plasma and the quality controls.

## AIM

To validate the analytical procedure of an ETP-based APCr assay according to the regulatory standard ICHQ2R1 and CLSI guidelines.<sup>3</sup>

## METHOD

- ❖ Three quality controls (QCs) representing plasmas with different levels of coagulation and one reference plasma (Ref plasma) were used.
- ❖ The method targets a 90% inhibition of the ETP in a pool of plasma from healthy donors (10 men and 10 women not using hormonal contraception, with no coagulation abnormalities [i.e. FV Leiden nor G20210A mutation carrier]) in presence of APC compared to the same condition in absence of APC. [► Figure 1]

$$\text{Inhibition \%} = 100\% - \frac{\text{Sample ETP (+TM)}}{\text{Sample ETP (-TM)}}$$




Figure 1 : Thrombin generation in absence of APC (blue curve) and in presence of APC (red curve).

- ❖ As the pool of healthy donors is not produced at large scale, specific algorithms are applied to the commercial reference plasma to correlate with the pool.

## RESULTS

- ❖ Limits of acceptability of QCs and Ref plasma [► Table 1] were defined as
  - the mean of results obtained in the entire study (N=24)  $\pm 2 \times \text{SD}$
  - SD = the highest CV of the accuracy study \* the mean of the entire accuracy study

QC low (hypocoagulable)	100 $\pm$ 0%
QC intermediate (intermediate coagulable)	45 $\pm$ 15 %
QC high (hypercoagulable)	12 $\pm$ 10%
Ref plasma	89 $\pm$ 6%

Table 1 : Limits of acceptability (mean  $\pm 2 \times \text{SD}$ ) of QCs and Ref plasma.

- ❖ Intra-run (into a same plate) and inter-run (between plates) repeatability passed the acceptance criteria : <10% of standard deviation. [► Table 2]

	Intra-run variability [SD]	Inter-run variability [SD]
QC low (hypocoagulable)	0%	0%
QC intermediate (intermediate coagulable)	1%	7%
QC high (hypercoagulable)	3%	4%
Reference plasma	0%	3%

Table 2 : Intra- and inter-run repeatability (expressed in SD). Intra-run repeatability was based on 5 measurements of the Ref plasma and QCs and inter-run repeatability was based on 10 runs measuring the Ref plasma and QCs, performed by the same operator.

- ❖ Intermediate precision passed the acceptance criteria : standard deviation <10% and no significant difference between operators. [► Table 3]

	Operator 1 [SD]	Operator 2 [SD]	Operator 3 [SD]	p-value
QC low (hypocoagulable)	0%	0%	0%	0.8503
QC intermediate (intermediate coagulable)	4%	5%	2%	0.6969
QC high (hypercoagulable)	3%	4%	0%	0.8253
Reference plasma	2%	2%	1%	0.9459

Table 3 : Intermediate precision (expressed in SD and p-value) based on 3 runs measuring the ref plasma and QCs and performed by 3 different operators.

- ❖ The assay demonstrated a curvilinear dose-response to protein S and APC concentrations ( $R^2 > 0.99$ ). [► Figure 2 and ► figure 3]




Figure 2: Inhibition percentage depending on a protein S deficiency. Vertical dotted line represents the limit of detection of the STA<sup>®</sup>-StaClot<sup>®</sup> protein S kit.




Figure 3: Inhibition percentage depending on concentration of spiked APC. Horizontal dotted line represents 90% inhibition.

- ❖ Analysis of plasma samples from 50 healthy individuals (22 women not taking combined oral contraceptive (COC) and 28 men, no FV Leiden carrier) confirmed the validity of the tests [acceptance criteria: mean = 90% ( $\pm 2,5\%$ )] with a mean inhibition percentage of 89%.
- ❖ Investigations in women taking COC confirmed the good sensitivity of the assay. [► Figure 4]




Figure 4: Inhibition percentage of healthy individuals (blue) and women using COC (red). The dotted green line represents 90% inhibition.

## CONCLUSION

This study is the first describing the validation of ETP-based APCr assay according to regulatory standards.

It provides the stakeholders, the regulatory bodies and the physicians with a reproducible, sensitive and validated assay.

This will allow study-to-study comparison as well as perspectives for the establishment of specific thresholds to reflect the prothrombotic state in the individual patient.

### Conflict of Interest :

Jonathan Douxfils reports personal fees from Daiichi Sankyo, Diagnostica Stago, Roche and Roche Diagnostics outside the submitted work. Jonathan Douxfils is the CEO and founder of QUALIBlood s.a.